Single domain antibodies to programmed cell death (PD-1)
The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
1. An isolated single domain antibody that binds to human PD-1 but does not block the interaction of human PD-1 with human PD-L1 and/or PD-L2, wherein said single domain antibody is a human heavy chain variable domain (VH) comprising a CDR1, 2, and 3 having the following sequences SEQ ID NOs: 173, 174, and 175, respectively.
2. The isolated single domain antibody according to claim 1 , wherein said isolated single domain antibody comprises the following V H sequence of SEQ ID NO.
3. The isolated single domain antibody according to claim 1 , wherein said single domain antibody is conjugated to a toxin, enzyme, radioisotope, half-life extending moiety, label, therapeutic molecule or other chemical moiety,
optionally wherein said half-life extending moiety is selected from the group consisting of an albumin binding moiety, a transferrin binding moiety, a polyethylene glycol molecule, a recombinant polyethylene glycol molecule, human serum albumin, a fragment of human serum albumin, and an albumin binding peptide or single domain antibody that binds to human serum albumin.
4. The isolated single domain antibody according to claim 1 that does not compete with an antibody that blocks the interaction of PD-1 with PD-L1 and/or the interaction of PD-1 with PD-L2, and/or wherein the isolated single domain antibody is obtained or obtainable from a transgenic rodent that expresses a transgene comprising human V, D and J regions, optionally wherein said rodent does not produce any functional endogenous light and heavy chains.
5. An isolated binding agent comprising a single domain antibody according to claim 1 , wherein said single domain antibody is linked to a second binding molecule that does not bind to PD-1, optionally wherein said second binding molecule binds to an immunooncology target, or wherein said single domain antibody is linked to a second binding molecule that binds to PD-1, optionally wherein said second binding molecule blocks the interaction of PD-1 with PD-L1 and/or PD-L2 or wherein said single domain antibody is conjugated to a toxin, enzyme, radioisotope, half-life extending moiety, therapeutic molecule or other chemical moiety, optionally wherein said half-life extending moiety is selected from the group consisting of an albumin binding moiety, a transferrin binding moiety, a polyethylene glycol molecule, a recombinant polyethylene glycol molecule, human serum albumin, a fragment of human serum albumin, or an albumin binding peptide or single domain antibody that binds to human serum albumin.
6. An immunoconjugate comprising the single domain antibody of claim 1 , wherein the single domain antibody is linked to a therapeutic agent, optionally wherein said therapeutic agent is a toxin, enzyme, radioisotope or other chemical moiety.
7. A pharmaceutical composition comprising a single domain antibody of claim 1 and a pharmaceutical carrier.
8. A kit comprising a single domain antibody according to claim 1 and instructions for use.
9. A bispecific molecule comprising the single domain antibody of claim 1 linked to a second functional moiety having a different binding specificity than said single domain antibody, optionally, wherein said second moiety is an antibody, an antibody fragment or antibody mimetic, optionally wherein said second moiety binds to an immunooncology target.
10. A multivalent binding agent comprising a single domain antibody, wherein said binding agent comprises two single domain antibodies wherein a first single domain antibody is according to claim 1 , and wherein the second single domain antibody that binds to human PD-1 also blocks the interaction with human PD-L1 and/or PD-L2 and wherein said first single domain antibody is linked to the second single domain antibody.